Quince Therapeutics, Inc.
QNCX
$1.63
$0.021.24%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -28.82% | -3.66% | -31.62% | -22.15% | 10.97% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.91% | 49.13% | 30.22% | 40.24% | 58.35% |
| Operating Income | -11.91% | -49.13% | -30.22% | -40.24% | -58.35% |
| Income Before Tax | 42.29% | -34.76% | -40.80% | -2.39% | -466.78% |
| Income Tax Expenses | 86.11% | 51.61% | -86.27% | -- | -- |
| Earnings from Continuing Operations | 42.12% | -34.81% | -40.07% | -2.64% | -467.52% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 42.12% | -34.81% | -40.07% | -2.64% | -467.52% |
| EBIT | -11.91% | -49.13% | -30.22% | -40.24% | -58.35% |
| EBITDA | -12.07% | -49.45% | -37.08% | -38.83% | -57.59% |
| EPS Basic | 46.57% | -31.94% | -31.58% | 14.23% | -373.09% |
| Normalized Basic EPS | -74.00% | -50.88% | -59.88% | -20.50% | -35.29% |
| EPS Diluted | 46.57% | -31.94% | -31.58% | 14.23% | -373.09% |
| Normalized Diluted EPS | -74.00% | -50.88% | -59.88% | -20.50% | -35.29% |
| Average Basic Shares Outstanding | 8.33% | 2.16% | 6.45% | 19.66% | 19.99% |
| Average Diluted Shares Outstanding | 8.33% | 2.16% | 6.45% | 19.66% | 19.99% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |